GlassScriptPhysician profile
Christopher Housden
NPI 1982130936
$9,621.49
in general payments reported to CMS, 2019-2025
53 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.42 · 2020: $640 · 2021: $2,118 · 2022: $1,804 · 2023: $1,959 · 2024: $1,298 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.40 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,312.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $911.08 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $894.20 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.50 | 2020-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $473.35 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $463.55 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.26 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $375.36 | 2020-2025 | Trintellix |
| Pfizer INC. | $352.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.06 | 2020-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $287.85 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $284.84 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $281.72 | 2020-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $279.55 | 2021-2025 | Rexulti |
| Boston Scientific Corporation | $255.71 | 2023-2025 | Wavewriter Alpha Prime 16 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Housden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.